Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2025.

According to an AGM resolution, the Nomination Committee 2024-2025 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2024 and the Chairman of the Board.
 
Work on composing the Nomination Committee is now completed, and this year’s Nomination Committee consists of:
 
Karl Tobieson, appointed by Linc AB
Richard Torgerson, appointed by Nordea Funds AB
Anders Hallberg, appointed by Hallberg Management AB
Uli Hacksell, Chairman of the Board, Medivir AB
 
The 2025 Annual General Meeting of Medivir will be held on Wednesday May 7, 2025.

Datum 2024-10-23, kl 10:45
Källa MFN
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.